Pharmaceutical Companies Turn to AscellaHealth Family of Companies for Consultative Business Model, Including Robust Pre-Commercialization and Market Access Services

Manufacturers discover an experienced, trusted resource for a full range of services from pre-commercialization and market access to distribution and fulfillment, compliance and monitoring to patient services for enhanced patient outcomes.

As Specialty Pharmacy continues to gain market traction, specialty drug manufacturers are seeking innovative approaches to effectively launch new products, manage care coordination and offset the high cost of expensive medications for patients. Many are partnering with global healthcare and Specialty Pharmacy (SP) solutions providers, like the AscellaHealth Family of Companies, for an end-to-end solution with capabilities that can more effectively and efficiently serve patients from diagnosis to medication access and across their entire treatment journey.

Because not all SP solution providers can deliver a full range of services, it is advantageous for manufacturers to collaborate with a partner that can support the complete range of programs needed to ease the administrative burden of managing multiple vendors. These services span the complete launch of specialty products, from pre-commercialization through all stages of the product life cycle, including fulfillment and outcomes tracking.

The comprehensive portfolio of services provided by the AscellaHealth Family of Companies results in streamlined access to therapy, optimal clinical results and an enhanced patient journey. Moreover, these high-touch SP capabilities ensure increased access to and compliance with specialty pharmaceuticals so patients can achieve the best possible outcome and treatment experience.

The key to a successful specialty drug launch is to gain market access and product uptake through identification of targeted patient populations and developing strong relationships with them, as well as payers and provider networks.

The AscellaHealth Family of Companies offers deep global market understanding and a vast range of capabilities to pharmaceutical manufacturers for a multi-pronged, productive market entry with the benefit of having to manage only a single vendor.

Introducing the AscellaHealth Family of Companies

AscellaHealth’s market position is now even stronger as it joins together with its subsidiaries, Optime Care and Terebellum, to form the AscellaHealth Family of Companies, providing services to all segments of the specialty pharmacy and rare disease industry.

• Optime Care is a nationally recognized pharmacy, distribution and patient management organization that creates the trusted path for patients with rare and orphan disorders. They offer pharmaceutical manufacturers an exclusive distribution model with specific financial advantages, as well as dedicated, branded teams to develop custom programs relating to new product launches and a full suite of patient support and HUB services to increase compliance to therapy.
• Terebellum is an Ireland-based subsidiary with expansion plans throughout Germany and the UK, offering premier European market access and payer expertise, supply chain logistics and distribution, and unique pharmaceutical financial solutions, such as loan-based assistance to Life Sciences partners and other industry stakeholders.

These partnerships will further enhance our global market position as an industry innovator and guide our expansion, which has reached an impressive 1,556% four-year revenue increase based on organic growth and acquisitions.

What’s more, our expanded AscellaHealth Family of Companies leadership team has the depth of experience necessary to provide consultative support to all stakeholders within the industry for the development of custom programs that enhance outcomes and quality of life for patients.

Range of Critical Services

The AscellaHealth Family of Companies comprehensive suite of services includes:

• Outsourced market access capabilities
• Wholesale, exclusive distribution and third-party logistics services
• National limited distribution drug (LLD) fulfillment
• Clinical patient support/Hub services
• Outcomes tracking and data analytics
• Financial Assistance programs
• Group Purchasing Services

Access

Product commercialization and outsourced market access services ensure that specialty patients have access to the therapies they need when they need them most. The AscellaHealth Family of Companies has the deep payer expertise to negotiate with payers on behalf of drug manufacturers, ensuring seamless access to therapies, while optimizing outcomes for rare and ultra-orphan diseases. We can collaborate with a market access group or function as an outsourced team.

Communication

With comprehensive patient support and Hub capabilities that span the entire product life cycle and prescription process, our approach serves to streamline communications between prescriber, patient and pharmacy, decrease time to fill, increase patient engagement and optimize outcomes. Technology-based communication tools and algorithms are utilized by our expert call center to engage patients, break down barriers to communication and ensure optimal therapeutic outcomes.

Financial Assistance

To further serve market stakeholders, our team also developed and implemented a suite of unique Financial Assistance programs for high-cost gene/cell therapies and other expensive specialty medications. Other custom copay program options include the important work of patient care coordinators who offer the broad specialty therapeutic expertise needed to rapidly identify copay assistance and other financial resources necessary for patients to start and stay on therapy as prescribed.

Single Vendor

What’s more, manufacturers reap the benefits of working with and managing a single vendor for all program and drug launch milestones. This means the data they receive will be from one source and purely actionable. Manufacturers can choose only the services they need, whether it’s all of the capabilities or a la carte.

The AscellaHealth Family of Companies is well ahead of the marketplace trend of manufacturers shifting away from multiple big box vendors and opting instead for an all-inclusive vendor which offers white-glove support and service.

Optime Care’s Patient-First Approach

AscellaHealth Family of Companies subsidiary Optime Care offers a patient-first approach that puts the patient at the center of care by utilizing patient care coordinators who are well versed in all rare and SP conditions. We also offer dedicated, branded teams for each manufacturer. Such high-level care coordination strengthens communication, yields rich data for more informed decision-making and improves the overall patient experience. This approach also empowers clinical teams to seamlessly eliminate treatment gaps for the patient.

The Optime Care model helps support streamlined patient access to prescribed high-cost therapies for complex conditions and rare diseases, with drug therapy monitored for effectiveness, compliance and adherence to treatment that leads to optimized health outcomes.

Manufacturers should view partnering with the AscellaHealth Family of Companies as an opportunity to ensure a successful drug launch inclusive of enhanced product access, compliance to therapy, increased brand loyalty and optimal patient outcomes.